• Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S2670 A-674563 72 mg/mL 72 mg/mL 18 mg/mL
S1582 H 89 2HCl 6 mg/mL 104 mg/mL <1 mg/mL
S2554 Daphnetin <1 mg/mL 35 mg/mL <1 mg/mL
S7563 AT13148 <1 mg/mL 62 mg/mL <1 mg/mL
S7857 8-Bromo-cAMP 80 mg/mL 5 mg/mL <1 mg/mL
S7858 Dibutyryl-cAMP (Bucladesine) 98 mg/mL 98 mg/mL 19 mg/mL
Catalog No. Information Product Use Citations Product Validations


A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.


H 89 2HCl

H 89 2HCl is a potent PKA inhibitor with Ki of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II.



Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.



AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.



8-bromo-cAMP is a cell permeable analog of cAMP that activates cyclic-AMP-dependent protein kinase with a Ka value of 0.05 μM; and a PKA activator.


Dibutyryl-cAMP (Bucladesine)

Dibutyryl-cAMP (Bucladesine) is a cell-permeable PKA activator by mimicing the action of endogenous cAMP.